$2.45 Billion is the total value of Tekla Capital Management LLC's 197 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 35.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMGN | Buy | Amgen Inc. | $134,461,000 | +0.5% | 729,658 | +3.6% | 5.49% | +1.0% |
| GILD | Buy | Gilead Sciences, Inc. | $124,048,000 | +9.1% | 1,836,112 | +5.0% | 5.06% | +9.6% |
| VRTX | Buy | Vertex Pharmaceuticals Inc. | $89,807,000 | +10.0% | 489,734 | +10.4% | 3.66% | +10.6% |
| MRK | Buy | Merck & Co., Inc. | $84,998,000 | +2.9% | 1,013,695 | +2.1% | 3.47% | +3.4% |
| ALXN | Buy | Alexion Pharmaceuticals, Inc. | $52,394,000 | +3.2% | 400,014 | +6.5% | 2.14% | +3.6% |
| REGN | Buy | Regeneron Pharmaceuticals, Inc. | $52,261,000 | -10.1% | 166,968 | +18.0% | 2.13% | -9.6% |
| ABT | Buy | Abbott Laboratories | $42,399,000 | +16.0% | 504,148 | +10.3% | 1.73% | +16.6% |
| CVS | Buy | CVS Health Corp. | $31,354,000 | +14.8% | 575,401 | +13.6% | 1.28% | +15.3% |
| ISRG | Buy | Intuitive Surgical, Inc. | $29,204,000 | +27.1% | 55,675 | +38.2% | 1.19% | +27.8% |
| BSX | Buy | Boston Scientific Corporation | $27,174,000 | +49.5% | 632,250 | +33.5% | 1.11% | +50.3% |
| NVS | Buy | Novartis AGsponsored adr | $25,297,000 | -5.0% | 277,047 | +0.1% | 1.03% | -4.5% |
| ABBV | Buy | AbbVie Inc. | $24,239,000 | -6.1% | 333,316 | +4.1% | 0.99% | -5.6% |
| BMRN | Buy | BioMarin Pharmaceutical Inc. | $21,050,000 | +6.7% | 245,763 | +10.7% | 0.86% | +7.2% |
| SAGE | Buy | Sage Therapeutics, Inc. | $15,406,000 | +21.3% | 84,145 | +5.4% | 0.63% | +21.9% |
| PRAH | Buy | PRA Health Sciences, Inc. | $15,170,000 | -4.2% | 153,003 | +6.6% | 0.62% | -3.7% |
| BAX | Buy | Baxter International Inc. | $14,472,000 | +29.3% | 176,698 | +28.4% | 0.59% | +29.9% |
| BLUE | Buy | bluebird bio, Inc. | $12,964,000 | -9.5% | 101,918 | +12.0% | 0.53% | -9.1% |
| EW | Buy | Edwards Lifesciences Corp. | $12,889,000 | +18.6% | 69,769 | +22.8% | 0.53% | +19.3% |
| MCK | Buy | McKesson Corp. | $12,860,000 | +55.4% | 95,691 | +35.3% | 0.52% | +56.2% |
| HUM | Buy | Humana Inc. | $12,767,000 | +34.5% | 48,122 | +34.9% | 0.52% | +35.3% |
| ABC | Buy | AmerisourceBergen Corp. | $11,960,000 | +89.8% | 140,273 | +77.1% | 0.49% | +90.6% |
| ALNY | Buy | Alnylam Pharmaceuticals, Inc. | $11,709,000 | -6.1% | 161,372 | +20.9% | 0.48% | -5.7% |
| GWPH | Buy | GW Pharmaceuticals PLCads | $11,119,000 | +89.0% | 64,499 | +84.9% | 0.45% | +90.0% |
| FGEN | Buy | FibroGen, Inc. | $11,038,000 | +15.6% | 244,320 | +39.0% | 0.45% | +16.0% |
| ABMD | Buy | ABIOMED, Inc. | $8,522,000 | +24.4% | 32,716 | +36.4% | 0.35% | +25.2% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $8,480,000 | +17.4% | 73,647 | +20.0% | 0.35% | +18.1% |
| IONS | Buy | Ionis Pharmaceuticals, Inc. | $8,201,000 | -7.9% | 127,598 | +16.3% | 0.34% | -7.5% |
| AGIO | Buy | Agios Pharmaceuticals, Inc. | $7,250,000 | +17.1% | 145,342 | +58.4% | 0.30% | +17.9% |
| PTCT | Buy | PTC Therapeutics, Inc. | $6,282,000 | +143.1% | 139,608 | +103.4% | 0.26% | +143.8% |
| ZGNX | Buy | Zogenix, Inc. | $5,932,000 | +20.1% | 124,148 | +38.3% | 0.24% | +20.4% |
| IMMU | Buy | Immunomedics, Inc. | $5,400,000 | -2.3% | 389,313 | +35.3% | 0.22% | -1.8% |
| EPZM | Buy | Epizyme, Inc. | $5,015,000 | +39.8% | 399,604 | +38.1% | 0.20% | +40.4% |
| LGND | Buy | Ligand Pharmaceuticals Inc. | $5,029,000 | +33.8% | 44,055 | +47.4% | 0.20% | +34.0% |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $4,281,000 | +52.2% | 160,147 | +52.9% | 0.18% | +53.5% |
| ANAB | Buy | AnaptysBio, Inc. | $4,220,000 | -12.3% | 74,798 | +13.6% | 0.17% | -11.8% |
| UTHR | Buy | United Therapeutics Corporationclass b | $4,223,000 | -12.8% | 54,094 | +31.1% | 0.17% | -12.7% |
| MASI | Buy | Masimo Corp. | $4,127,000 | +178.5% | 27,732 | +158.8% | 0.17% | +180.0% |
| HZNP | New | Horizon Therapeutics plcshares | $3,789,000 | – | 157,473 | +100.0% | 0.16% | – |
| THC | Buy | Tenet Healthcare Corp. | $3,774,000 | -7.3% | 182,671 | +29.4% | 0.15% | -6.7% |
| ALC | New | Alcon Inc.ordinary shares | $3,436,000 | – | 55,369 | +100.0% | 0.14% | – |
| BCEL | New | Atreca, Inc. | $3,297,000 | – | 175,000 | +100.0% | 0.14% | – |
| LIVN | Buy | LivaNova PLCshares | $3,287,000 | +196.4% | 45,681 | +300.7% | 0.13% | +197.8% |
| A | New | Agilent Technologies, Inc. | $2,509,000 | – | 33,600 | +100.0% | 0.10% | – |
| HQY | New | HealthEquity, Inc. | $2,080,000 | – | 31,810 | +100.0% | 0.08% | – |
| HOLX | Buy | Hologic, Inc. | $2,051,000 | +116.8% | 42,701 | +118.5% | 0.08% | +121.1% |
| CRL | Buy | Charles River Laboratories International, Inc. | $2,010,000 | +30.1% | 14,167 | +33.1% | 0.08% | +30.2% |
| NTUS | New | Natus Medical Inc. | $1,573,000 | – | 61,219 | +100.0% | 0.06% | – |
| WVE | Buy | WaVe Life Sciences Ltd.shares | $1,460,000 | +23.8% | 55,955 | +84.5% | 0.06% | +25.0% |
| TXMD | New | TherapeuticsMD, Inc. | $1,409,000 | – | 541,815 | +100.0% | 0.06% | – |
| EVH | Buy | Evolent Health, Inc. | $1,385,000 | +161.3% | 174,270 | +313.5% | 0.06% | +159.1% |
| MIST | New | Milestone Pharmaceuticals, Inc. | $1,358,000 | – | 50,000 | +100.0% | 0.06% | – |
| CNCE | Buy | Concert Pharmaceuticals, Inc. | $1,330,000 | +142.7% | 110,853 | +144.4% | 0.05% | +145.5% |
| MOR | New | MorphoSys AGsponsored ads | $957,000 | – | 39,643 | +100.0% | 0.04% | – |
| INGN | Buy | Inogen, Inc. | $935,000 | +22.5% | 14,000 | +75.0% | 0.04% | +22.6% |
| RGNX | New | REGENXBIO Inc. | $658,000 | – | 12,801 | +100.0% | 0.03% | – |
| CBAY | New | CymaBay Therapeutics, Inc. | $631,000 | – | 88,102 | +100.0% | 0.03% | – |
| RARX | New | Ra Pharmaceuticals, Inc. | $577,000 | – | 19,190 | +100.0% | 0.02% | – |
| CMRX | New | Chimerix, Inc. | $494,000 | – | 114,333 | +100.0% | 0.02% | – |
| FATE | New | Fate Therapeutics, Inc. | $495,000 | – | 24,379 | +100.0% | 0.02% | – |
| ABIO | New | ARCA biopharma, Inc. | $264,000 | – | 36,068 | +100.0% | 0.01% | – |
| NVAX | New | Novavax, Inc. | $167,000 | – | 28,550 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.